PMID- 23071863
OWN - NLM
STAT- MEDLINE
DCOM- 20130404
LR  - 20211203
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 5
IP  - 8
DP  - 2012
TI  - Phosphorylated mTOR expression correlates with poor outcome in early-stage triple 
      negative breast carcinomas.
PG  - 806-13
AB  - The mammalian target of rapamycin (mTOR) plays an important role in cell growth, 
      proliferation, and metabolism. Some studies have associated phosphorylated mTOR 
      (p-mTOR) expression with worse outcome in breast cancers. However, the 
      significance of p-mTOR expression specifically in triple negative breast 
      carcinoma (TNBC) is unknown. In this study, p-mTOR expression was evaluated by 
      immunohistochemistry in 172 TNBCs and the result was correlated with 
      clinicopathologic variables and disease outcome. The majority of tumors (72.1%) 
      were p-mTOR positive; p-mTOR expression did not correlate with age, tumor size, 
      grade, lymph node status, or tumor stage. In patients at stage 1 and 2 disease, 
      those with p-mTOR expression had significantly worse overall as well as 
      recurrence-free survival compared to those without p-mTOR expression. p-mTOR 
      expression appears to be an adverse prognostic indicator in early-stage TNBCs. 
      The assessment of p-mTOR expression in these tumors may also help to stratify 
      patients for future target therapy studies.
FAU - Ueng, Shir-Hwa
AU  - Ueng SH
AD  - Department of Pathology, Chang Gung Memorial Hospital Linko, Taiwan.
FAU - Chen, Shin-Cheh
AU  - Chen SC
FAU - Chang, Yu-Sun
AU  - Chang YS
FAU - Hsueh, Swei
AU  - Hsueh S
FAU - Lin, Yung-Chang
AU  - Lin YC
FAU - Chien, Hui-Ping
AU  - Chien HP
FAU - Lo, Yun-Feng
AU  - Lo YF
FAU - Shen, Shih-Che
AU  - Shen SC
FAU - Hsueh, Chuen
AU  - Hsueh C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121001
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/metabolism/mortality/*pathology
MH  - Carcinoma, Ductal, Breast/metabolism/mortality/*secondary
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Lymph Nodes
MH  - Lymphatic Metastasis
MH  - Phosphorylation
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Progesterone/*metabolism
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Taiwan/epidemiology
PMC - PMC3466984
OTO - NOTNLM
OT  - Phosphorylated mammalian target of rapamycin (p-mTOR)
OT  - breast cancer
OT  - triple negative
EDAT- 2012/10/17 06:00
MHDA- 2013/04/05 06:00
PMCR- 2012/10/01
CRDT- 2012/10/17 06:00
PHST- 2012/08/13 00:00 [received]
PHST- 2012/09/07 00:00 [accepted]
PHST- 2012/10/17 06:00 [entrez]
PHST- 2012/10/17 06:00 [pubmed]
PHST- 2013/04/05 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
PST - ppublish
SO  - Int J Clin Exp Pathol. 2012;5(8):806-13. Epub 2012 Oct 1.